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Abstract
Background: BAP1 and PBRM1 are frequently mutated in primary clear cell renal cell carcinoma (ccRCC) tumors;
however, the frequency and clinical relevance of these mutations in metastatic ccRCC tumors is unknown.
Additionally, while intra-tumor heterogeneity has been shown to be common in primary ccRCC, little is known
regarding heterogeneity in metastatic ccRCC tumors.
Materials and methods: We analyzed BAP1 and PBRM1 loss of protein expression in patient-matched primary and
metastatic tumors from 97 patients. Expression was determined using a validated immunohistochemistry assay,
which has been shown to be correlated with mutation status.
Results: Of the 97 patients evaluated, 20 and 57% showed loss of BAP1 and PBRM1 in their primary tumors,
respectively. Comparing expression across patient-matched primary-metastatic tumor pairs, 98 and 90% had
concordant BAP1 and PBRM1 expression, respectively. Both patients who demonstrated discordant BAP1
expression showed loss of BAP1 expression during progression to metastatic ccRCC. Similarly, seven of the ten
patients that demonstrated discordant PBRM1 expression showed loss of PBRM1 expression during progression to
metastatic ccRCC. We evaluated intra-metastatic tumor heterogeneity using 12 patients who had multiple blocks
available from the same tumor with representative pathology; 100 and 92% showed concordant BAP1 and
PBRM1 expression, respectively. Amongst 32 patients who had serial metastatic tumors available, both BAP1 and
PBRM1 had 97% concordant expression.
Conclusions: We observed minimal intra- and inter- tumor heterogeneity in metastatic ccRCC tumors. Patients
with discordant BAP1 or PBRM1 expression across their matched primary and metastatic tumors usually showed
loss of expression during progression to metastatic ccRCC.
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Background
Mutations that cause loss of expression of BAP1 and
PBRM1 are two of the most frequently occurring mo-
lecular events in primary clear cell renal cell carcinoma
(ccRCC) with a prevalence of approximately 10 and 40%,
respectively [1–3]. Both of these genes are located on
chromosome arm 3p, which is deleted in approximately
90% of ccRCC patients. While mutations in BAP1 and
PBRM1 have been shown to be associated with poor
cancer-specific survival [1, 4, 5], the frequency of these
mutations (and their clinical relevance) in metastatic
ccRCC tumors is unknown. Related to this, Gerlinger
and colleagues compared mutations from patient-
matched primary and metastatic tumors in four patients;
all four were BAP1 wild type and two had PBRM1 muta-
tions [6, 7]. One of the two patients with a PBRM1 mu-
tation (EV002) had a PBRM1 mutation in all six biopsies
from the primary tumor as well as in a biopsy from a
metastasis obtained at the time of disease progression
on everolimus treatment. The other patient with a
PBRM1 mutation (RMH004) had a mutation in three of
the five biopsies from the primary tumor and a different
PBRM1 mutation in a tumor thrombus from the renal
vein. The value of this initial exploration notwithstand-
ing, investigations focused on larger cohorts of patients
with matched primary and metastatic ccRCC tumors are
necessary to obtain estimates of the prevalence of BAP1
and PBRM1 mutations in metastatic ccRCC tumors and
to better inform the potential value of these alterations
as potential biomarkers for response to therapy.
When evaluating candidate tumor-based biomarkers for
metastatic ccRCC, it is important to acknowledge that
previous investigators have reported evidence of intra-
tumor molecular heterogeneity in primary ccRCC. Specif-
ically, authors of two studies evaluated molecular he-
terogeneity by performing DNA sequencing on serial
biopsies taken from multiple regions of primary ccRCC
tumors [6, 7]. In doing so, they observed spatial hetero-
geneity in every tumor evaluated and thus concluded that
a single tumor biopsy gives only a small glimpse into the
molecular profile of a primary ccRCC tumor. Of note, the
authors in each study did not account for tumor grade
and presence of necrosis in evaluating intra-tumor hetero-
geneity, two features that are well reported to be prognos-
tic indicators for patients with ccRCC. Thus, their
observation of intra-tumor molecular heterogeneity is not
surprising given that the multiple biopsies could represent
areas of the tumor with varying tumor purity as well as
different aggressive pathological features. In fact, ccRCC
biomarkers have been shown to be associated with patho-
logical features of aggressiveness [8–11]. Thus, with re-
spect to the aforementioned need to evaluate BAP1 and
PBRM1 in metastatic ccRCC, these efforts should account
for key underlying pathologic features of the tumor.
Motivated by gaps in the literature on BAP1 and PBRM1
in metastatic ccRCC, our objective was four-fold. First, we
evaluated whether loss of expression of BAP1 and PBRM1
is a molecular homogenous or heterogeneous event within
metastatic ccRCC tumors. Second, we determined the
prevalence of loss of BAP1 and PBRM1 expression in meta-
static ccRCC. Third, we assessed whether loss of BAP1 and
PBRM1 expression in metastatic tumors is associated with
cancer-specific outcome. Lastly, we evaluated the concord-
ance of loss of BAP1 and PBRM1 expression across
patient-matched primary and metastatic tumors in a large
cohort of ccRCC patients.
Methods
Patient selection and pathology review
We identified 111 patients at Mayo Clinic Rochester
who were treated surgically for ccRCC between 1990
and 2005, had synchronous (M1) or metachronous (M0
at presentation) ccRCC metastases, underwent metasta-
sectomy for at least one of their metastatic tumors and
had formalin-fixed, paraffin-embedded (FFPE) tissue
available from their primary tumor and at least one
metastatic tumor. For the purposes of this study, multi-
focal renal tumors and contralateral renal tumors were
not considered as metastatic. A single pathologist (JCC)
comprehensively reviewed all tumors to confirm histo-
logical subtype (1997 AJCC/UICC classification), 2010
tumor stage, 2012 ISUP tumor grade, tumor size, and
presence of coagulative tumor necrosis and sarcomatoid
differentiation. The FFPE block(s) that was most repre-
sentative of the tumor (highest grade and presence of
necrosis) was identified. If multiple blocks were identi-
fied as representative of the tumor, then all blocks were
analyzed in order to evaluate intra-tumor heterogeneity
across regions of the metastatic tumor that have equiva-
lent pathological features. This study was approved by
the Mayo Clinic IRB.
BAP1 and PBRM1
Five-μm thick FFPE sections were stained using a vali-
dated and published immunohistochemical (IHC) method
[2]. Blinded to the paired nature of the samples, each
stained slide was reviewed to determine loss of expression
of BAP1 and PBRM1. As described previously [1, 4, 5],
positive staining in the background stromal cells and
intratumoral lymphocytes was used as a positive internal
control. Tumors were categorized as PBRM1 (BAP1) posi-
tive when tumors expressed strong diffuse nuclear staining
and PBRM1 (BAP1) negative when tumor cells showed a
diffuse lack of nuclear staining. In a small number of
tumors only a distinct tumor nodule or area showed ab-
sent nuclear staining; these focal negative areas were
thought to represent subclones of the tumor. Since some
tumor cells showed lack of nuclear staining, they were
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deemed to be PBRM1 (BAP1) negative. Additionally, a
small number of tumors showed weak nuclear staining
and these weak positive cases were deemed PBRM1
(BAP1) positive. The IHC assays for BAP1 and PBRM1
have been validated and have been shown to be correlated
with mutation status [2, 4].
Statistical methods
Protein expression of PBRM1 and BAP1 were dichoto-
mized as positive or negative, as described above. Concord-
ance between patient-matched primary and metastatic
tumors was calculated as the percentage of pairs where the
primary and patient-matched metastatic tumor had the
same designation. Cox proportional hazards regression was
used to determine if expression in metastatic tumors was
associated with ccRCC-specific survival adjusting for age at
diagnosis; dichotomized expression was modeled as a time-
dependent covariate. If a patient had multiple simultaneous
metastases with discordant PBRM1 (BAP1) status, then the
tumor with loss of expression was used in the Cox model
[12]. For patients that had multiple blocks from the same
metastatic tumor stained for BAP1 and PBRM1 (to esti-
mate intra-metastatic tumor heterogeneity; each replicate
block had the same tumor grade and necrosis status) we
randomly chose one block to represent the metastatic




Our cohort entailed 111 patients who had a primary
ccRCC tumor and at least one ccRCC metastatic tumor
available for molecular staining (Table 1). A total of 158
patient-matched metastases were available for these 111
patients (Table 2 and Table 3). The median time from
nephrectomy to first metachronous metastasis was
1.80 years (min = 31 days, max = 10.73 years). Pulmonary
metastases were the most common, accounting for 38%
of all metastases (Table 2).
Concordance across patient-matched primary and metastatic
ccRCC tumors
BAP1
Of the available 111 patients, 97 (87%) primary
ccRCC tumors successfully stained for BAP1 (Table 1)
and 20% showed loss of BAP1 expression (IHC nega-
tive). We analyzed a total of 138 metastatic tumors
from these 97 patients. Overall concordance between
patient-matched primary and metastatic tumors from
the 97 patients was 98%: 100% in metachronous and
96% in synchronous metastatic tumors (Table 4).
With respect to the two patients with discordant
primary-metastatic tumor pairs, one patient had a
synchronous pulmonary metastasis and one patient
had a synchronous bone metastasis. The primary tumor
for both patients was IHC positive and the metastatic
tumors were IHC negative.
PBRM1
Ninety-seven (87%) primary tumors successfully stained
for PBRM1 (Table 1) and 57% showed loss of PBRM1
(IHC negative). Ninety-six of these 97 patients also had
BAP1 status available: 6 (6%) had loss of both BAP1 and
PBRM1, 49 (51%) had loss of PBRM1 only, 13 (14%) had
loss of BAP1 only and 28 (29%) lost neither BAP1 nor
PBRM1. For the 97 patients with staining of PBRM1 in
the primary tumor, we analyzed a total of 138 patient-
matched metastatic tumors. Overall concordance be-
tween patient-matched primary and metastatic tumors
from the 97 patients was 90%: 89% in metachronous and
90% in synchronous metastatic tumors (Table 4). Dis-
cordance was observed across metastatic sites. Of the 10
patients that had at least one discordant primary-
metastatic tumor pair, five had synchronous metastatic
tumors and five had metachronous metastatic tumors.
Among these 10 patients, seven (70%) demonstrated loss
of PBRM1 during progression to metastatic ccRCC.
Intra-metastatic tumor heterogeneity
Replicate blocks were analyzed for BAP1 and PBRM1 ex-
pression in 12 metastatic tumors in order to investigate
intra-tumor heterogeneity (median = 2, max = 5 replicate
blocks per metastatic tumor). Of these, we observed 100%
concordance in BAP1 status and 92% concordance in
PBRM1 status.
Concordance across longitudinal metastatic ccRCC tumors
BAP1 and PBRM1 staining was performed on longitu-
dinal metastatic tumors for 32 patients (median = 2,
max = 4 metastatic tumors per patient). We observed
inter-metastatic tumor heterogeneity of BAP1 in one
(3%) patient. The primary tumor for this patient was
BAP1 IHC positive, the first bone metastasis (synchron-
ous) was IHC negative and the second bone metastasis
(diagnosed approximately 9 months later) was IHC posi-
tive. Similarly, we observed inter-metastatic tumor
heterogeneity of PBRM1 in one (3%) patient. This pa-
tient had two available synchronous pulmonary metasta-
ses (i.e., at the time of surgery, these two metastases
were determined to be different pulmonary nodules): the
primary tumor was PBRM1 IHC positive, one pulmon-
ary nodule was IHC negative and the other pulmonary
nodule was IHC positive.
Associations of metastatic tumor expression with RCC-
specific survival
We did not observe a statistically significantly associ-
ation with ccRCC-specific survival for either metastatic
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expression of BAP1 (HR = 1.29, 95% confidence interval
(CI): 0.76–2.19, p = 0.34) or PBRM1 (HR = 0.92, 95% CI:
0.55–1.52, p = 0.79).
Discussion
Chromosome arm 3p loss is a common event in primary
ccRCC tumors and four of the most commonly mutated
genes are all located on 3p: VHL, BAP1, PBRM1 and
SETD2. We evaluated BAP1 and PBRM1 loss of protein
expression in a large cohort of patient-matched primary
and metastatic ccRCC tumors. Additionally, we examined
molecular heterogeneity in metastatic ccRCC tumors.
While previous investigators have reported evidence of
intra-tumor molecular heterogeneity in primary ccRCC
[6, 7], little is known regarding heterogeneity in meta-
static ccRCC tumors. The current research evaluating
intra-tumor heterogeneity in primary ccRCC tumors has
been performed comparing multiple biopsy samples de-
rived from the same tumor. Such analyses provide im-
portant information to determine if biopsy samples can
be used for selecting biomarker-based neoadjuvant sys-
temic therapy. Our objective herein was to determine if
intra-tumor molecular heterogeneity exists across mul-
tiple samples from the same surgically-resected tumor
that all have similar pathological feature. It is well
known that the drivers, in terms of behavior based on
conventional morphology, are tumor grade and necrosis
and the areas of a tumor with the highest grade and
presence of necrosis are likely enriched for the molecu-
lar drivers of metastasis. In fact, for studies evaluating
candidate tumor biomarkers, it has been suggested that
areas of high nuclear grade should be analyzed [12]. In-
deed, the concordance in morphology between patient-
matched primary and metastatic tumors supports this
recommendation [13]. Thus, we evaluated if intra-tumor
heterogeneity exists across samples from the same
tumor with similar pathological features. Similar analyses
have been performed comparing ccA/ccB ccRCC gene
expression subtypes for this cohort of patient-matched
Table 1 Clinical characteristics of the primary-metastatic cohort









No 15 (26.3%) 14 (25.9%) 29 (26.1%)
Yes 42 (73.7%) 40 (74.1%) 82 (73.9%)
Age at Surgery (years)
Mean 62.0 58.5 60.3
Median 63.6 59.1 61.4
Range (34.9–78.8) (38.2–73.7) (34.9–78.8)
Max Tumor Size (cm)
Mean 9.6 10.9 10.2
Median 9.0 10.0 9.5
Range (2.5–18.0) (2.1–23.0) (2.1–23.0)
2010 pT
Missing 0 1 1
1A 3 (5.3%) 1 (1.9%) 4 (3.6%)
1B 8 (14.0%) 8 (15.1%) 16 (14.5%)
2A 14 (24.6%) 6 (11.3%) 20 (18.2%)
2B 4 (7.0%) 5 (9.4%) 9 (8.2%)
3A 17 (29.8%) 20 (37.7%) 37 (33.6%)
3B 7 (12.3%) 4 (7.5%) 11 (10.0%)
3C 2 (3.5%) 1 (1.9%) 3 (2.7%)
4 2 (3.5%) 8 (15.1%) 10 (9.1%)
2010 pN
0 18 (31.6%) 20 (37.0%) 38 (34.2%)
1 4 (7.0%) 9 (16.7%) 13 (11.7%)
X 35 (61.4%) 25 (46.3%) 60 (54.1%)
TNM Stage
I 11 (19.3%) 0 (0.0%) 11 (9.9%)
II 18 (31.6%) 0 (0.0%) 18 (16.2%)
III 26 (45.6%) 0 (0.0%) 26 (23.4%)
IV 2 (3.5%) 54 (100.0%) 56 (50.5%)
Grade
1 1 (1.8%) 1 (1.9%) 2 (1.8%)
2 14 (24.6%) 5 (9.3%) 19 (17.1%)
3 32 (56.1%) 31 (57.4%) 63 (56.8%)
4 10 (17.5%) 17 (31.5%) 27 (24.3%)
BAP1 IHC in
Primary Tumor
Negative 13 (27.7%) 6 (12.0%) 19 (19.6%)




Negative 28 (60.9%) 27 (52.9%) 55 (56.7%)
Table 1 Clinical characteristics of the primary-metastatic cohort
and pathological information associated with the primary ccRCC
tumor (Continued)





1 34 (59.6%) 41 (75.9%) 75 (67.6%)
2 15 (26.3%) 12 (22.2%) 27 (24.3%)
3 6 (10.5%) 1 (1.9%) 7 (6.3%)
4 2 (3.5%) 0 (0.0%) 2 (1.8%)
aDenotes that the IHC stain was unsuccessful
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primary and metastatic tumors [14]. Herein, we ob-
served minimal intra- and inter-tumor heterogeneity of
BAP1 and PBRM1 loss of expression in metastatic
ccRCC tumors. Together, these results suggest that mul-
tiple samples from the same metastatic tumor may not
be necessary if stringent pathological review is incorpo-
rated. However, similar analyses should be performed on
additional molecular markers to verify that the results
are concordant for other markers.
Previous investigators have reported that BAP1 mutations
occur in approximately 10% of ccRCC tumors [1, 2, 4] and
loss of BAP1 expression is associated with reduced survival
[1]. The higher prevalence of loss of BAP1 expression
observed herein is likely due to our high-risk (metastatic)
cohort. We observed that loss of BAP1 protein expression
was nearly 100% concordant between patient-matched pri-
mary and metastatic tumors. This further underscores that
BAP1 is likely a truncal mutation and essential to both
ccRCC development and pathogenesis [7, 15]. The two pa-
tients that were discordant demonstrated loss of BAP1 dur-
ing progression to metastatic ccRCC, which suggests the
presence of a clone in the primary tumor that had lost
BAP1. While loss of BAP1 expression in primary ccRCC
tumors has been shown to be prognostic [1, 16], we did not
observe a statistically significant association in metastatic
ccRCC tumors. However, due to the low prevalence of loss
of BAP1 expression, associations with outcome should be
examined in larger cohorts of metastatic ccRCC tumors.
PBRM1 mutations have been shown to be prevalent in
approximately 40% of ccRCC tumors [1, 3, 4] and loss of








Median 1999 1998 1999
Range (1991–2005) (1990–2004) (1990–2000)
Metastatic Site
BONE 9 (10.0%) 10 (14.7%) 19 (12.0%)
BOWEL 1 (1.1%) 0 (0.0%) 1 (0.6%)
BRAIN 7 (7.8%) 4 (5.9%) 11 (7.0%)
CONTRALATERAL ADRENAL 3 (3.3%) 5 (7.4%) 8 (5.1%)
HEART 0 (0.0%) 1 (1.5%) 1 (0.6%)
IPSILATERAL ADRENAL 2 (2.2%) 8 (11.8%) 10 (6.3%)
LIVER 4 (4.4%) 5 (7.4%) 9 (5.7%)
MUSCLE 0 (0.0%) 1 (1.5%) 1 (0.6%)
NON-REGIONAL NODES 9 (10.0%) 1 (1.5%) 10 (6.3%)
OMENTUM 0 (0.0%) 1 (1.5%) 1 (0.6%)
OTHER 6 (6.7%) 8 (11.8%) 14 (8.9%)
PANCREAS 5 (5.6%) 2 (2.9%) 7 (4.4%)
PULMONARY 40 (44.4%) 20 (29.4%) 60 (38.0%)
SKIN 2 (2.2%) 2 (2.9%) 4 (2.5%)
SPLEEN 1 (1.1%) 0 (0.0%) 1 (0.6%)
THYROID 1 (1.1%) 0 (0.0%) 1 (0.6%)
Metastatic Grade
2 16 (17.8%) 13 (19.1%) 29 (18.4%)
3 60 (66.7%) 36 (52.9%) 96 (60.8%)
4 14 (15.6%) 19 (27.9%) 33 (20.9%)
Metastatic Necrosis
No 57 (63.3%) 38 (55.9%) 95 (60.1%)
Yes 33 (36.7%) 30 (44.1%) 63 (39.9%)
Metastatic Sarcomatoid
No 86 (95.6%) 62 (91.2%) 148 (93.7%)
Yes 4 (4.4%) 6 (8.8%) 10 (6.3%)
Eckel-Passow et al. BMC Urology  (2017) 17:19 Page 5 of 7
PBRM1 expression has been shown to be associated with
overall survival [4]. The higher prevalence of loss of
PBRM1 expression observed herein is likely due to the
cohort of high-risk patients. We observed a negative
genetic interaction between BAP1 and PBRM1, confirm-
ing a result that was reported previously [5]. Under inde-
pendence we would have expected 11% of the primary
tumors to show loss of both BAP1 and PBRM1; how-
ever, 6% of our primary tumors had loss of expression
for both genes. We observed high concordance of loss of
PBRM1 expression between patient-matched primary
and metastatic tumors. Of the 10 patients that
demonstrated discordance, 70% had primary tumors that
were IHC positive and subsequently the metastatic tu-
mors demonstrated PBRM1 loss of expression. This cor-
roborates our findings that when patient-matched
primary and metastatic tumors had discordant ccA/
ccB molecular subtype, 80% of these discordant pa-
tients progressed from having a primary tumor classi-
fied as ccA and a metastatic tumor classified as ccB
[14]. Furthermore, when evaluating pathological char-
acteristics across patient-matched primary and meta-
static RCC tumors, trends for higher grade and tumor
necrosis in the metastatic tumor have been observed
[13]. Overall, our results suggest that there may be a
clone in the primary tumor that had lost PBRM1. Discord-
ance was observed across multiple metastatic sites, and
thus, does not appear to be site specific. Additionally, we
did not observe an association between metastatic PBRM1
expression and ccRCC-specific survival.
We acknowledge that there may be systematic differ-
ences between subjects who underwent metastasectomy
and subjects with distant metastases that were not
treated surgically. However, tissue will only be available
from patients undergoing metastasectomy, so this limita-
tion is unavoidable. We used IHC to measure BAP1 and
PBRM1 protein loss instead of directly determining
BAP1 and PBRM1 mutation status. Thus, even though
the IHC assays for BAP1 and PBRM1 have been vali-
dated and shown to be correlated with mutation status
in previous studies [2, 4], the impact of mutations in
these proteins could not be determined. IHC is both
more cost effective and easily applied to formalin-fixed
paraffin-embedded specimens, which are both important
considerations when attempting to analyze hundreds of
clinically-stored tissue specimens. We only analyzed
metastatic tumors from patients whom we also had a
patient-matched surgically-resected primary ccRCC
tumor available for analysis. Because we ignored meta-
static tumors from patients who did not have a nephrec-
tomy at our institution, we may have a biased sample of
metastatic tumors. Thus, future studies examining the
molecular characteristics of metastatic tumors and iden-
tification of prognostic markers should evaluate all avail-
able metastatic tumors.
Conclusions
We observed minimal molecular heterogeneity across
sections from the same metastatic tumor that had
similar pathological features. With respect to progres-
sion from primary-to-metastatic ccRCC, loss of BAP1
and PBRM1 expression demonstrated minimal hetero-
geneity. Thus, BAP1 and PBRM1 are likely key events
in both ccRCC development and progression to me-
tastasis. Currently, the presence or absence of either
of these mutations does not guide clinical decision
Table 4 Percent (%) concordance across primary-metastatic




M0 at presentation 89.1 100
M1 90.2 96.0
Pulmonary 85.3 97.1
M0 at presentation 82.4 100
M1 88.2 94.1
Non-pulmonary 92.1 98.4
M0 at presentation 93.1 100
M1 91.2 97.0







Grade 1 2 2 (1.3)
1 3 1 (0.6)
2 2 11 (7.0)
2 3 17 (10.8)
3 2 14 (8.9)
3 3 64 (40.5)
3 4 12 (7.6)
4 2 2 (1.3)
4 3 14 (8.9)
4 4 21 (13.3)
Necrosis No No 52 (32.9)
No Yes 16 (10.1)
Yes No 43 (27.2)
Yes Yes 47 (29.7)
Sarcomatoid No No 136 (86.1)
No Yes 4 (2.5)
Yes No 12 (7.6)
Yes Yes 6 (3.8)
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making, especially in regards to choosing therapy for
metastatic disease. However, there are multiple poten-
tial therapeutic targets where these mutations could
be clinically relevant in the future. And, given the high
concordance of these mutations between primary and
metastatic tumors, testing the more readily-available
primary tumor might be sufficient. Going forward,
analyzing serial samples from the same patient and
mapping the clonal evolution of ccRCC will aid in un-
derstanding the molecular alterations that underlie
ccRCC pathogenesis [6, 7, 17–22]. As demonstrated
herein, this approach needs to be taken using larger
cohorts and associations with pathological features
and outcome should be conducted.
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